The Effect Of EGFR-TKIs In Lymphangiogenesis Of Lung Cancer With EGFR Mutations

[Purpose]To Explore and study The effect of EGFR-TKIs in lymphangiogenesis oflung cancer with EGFR mutation, explore the role of EGFR target therapy ofpotential inhibition of lymphangiogenesis in the treatment of lung cancer.[Methods]Use H1975lung cancer cell lines with EGFR mutations toconstructmouse xenograft models. The mice were devided into two groups,EGFR-TKIs treatedand solvent control group.The effect of EGFR-TKIs was observed.Using lymphatic endothelial-specific antibody D2-40and immunohistochemicalmethods, the densities, areas and maximum diameters of lymphangiogenesis wereobserved. And the impact of EGFR-TKIs on lung cancer lymphangiogenesis wasinvestigated.[Results]Tumor weights(p=0.035) and tumor relative volumes(p=0.031) ofEGFR-TKIs fedding groups were less than placebo fedding groups. The averagedensity of lymphangiogenesis of EGFR-TKIs fedding groups was6.44,and theaverage density of lymphangiogenesis of placebo fedding groups was10.70.So theaverage density of lymphangiogenesis of EGFR-TKIs fedding groups was lower thanplacebo fedding groups (p=0.023).The average areas(p=0.006),the average longestdiameters(p=0.004) of EGFR-TKIs fedding groups were less than placebo feddinggroups. The effect of EGFR-TKIs on lymphatic vessels invasion was limited (P=0.519).[Conclusions]The stain effect of D2-40on lymphangiogenesis was special.In lungcancer with EGFR mutations,EGFR-TKIs can inhibit tumor growth, reduce tumorweight and volume.EGFR-TKIs can inhibit the reproduction and expansion oflymphangiogenesis.